ALZARROK BIO, LLC Advances Promising Peptide Drug to Halt Alzheimer's Disease Progression

Alzheimer's disease is a multifactorial condition with a complex pathogenesis. Currently, there is no effective treatment available to halt its progression. ALZARROK BIO, LLC is an emerging biotech company that is built upon the groundbreaking research conducted by Anne Kasus-Jacobi, Ph.D. at the University of Oklahoma Health Sciences Center. The primary focus of ALZARROK is the development of a highly promising peptide drug, complemented by a superior delivery system, with the goal of halting the decline in cognitive function associated with this debilitating disease.

ALZARROK's patent-pending, multi-targeted peptide offers an efficient and synergistic approach to inhibit both neuroinflammation and neurodegeneration. This therapeutic peptide is being specifically designed for intranasal delivery, which is expected to provide two significant advantages over intravenous administration: first, it will enhance targeting efficiency and minimize degradation, and second, it will allow for convenient selfadministration by patients.

In a recent milestone, ALZARROK secured a Pre-Seed investment from i2E. This Pre-Seed funding, combined with matching funds from various state and federal agencies, is projected to cover the costs of crucial early pre-clinical experiments. These pre-clinical and preInvestigational New Drug (IND) studies will be conducted in full compliance with FDA requirements, providing ALZARROK the data needed for a strong IND application.